Redwood City, CA, and Hilden, Germany 1/7/19—QIAGEN has announced investments in one company and the purchase of the assets of another. QIAGEN has acquired N-of-One for an undisclosed amount. N-of-One adds to QIAGEN’s decision-support solutions for clinical interpretation of genomic data. “N-of-One has made tremendous strides in molecular oncology decision support, and their combination with QIAGEN’s own pre-curated knowledge base of evidence will provide powerful new tools to expand our abilities to deliver patient-specific insights,” stated Jonathan Sheldon, senior vice president of QIAGEN’s Bioinformatics Business Area. N-of-One’s MarkerMine database will be integrated with QIAGEN Clinical Insight, a genomics analysis and interpretation platform, to support oncology. N-of-One capabilities include case-specific reporting based on molecular diagnostics, support for biomarker evidence and therapeutic options, clinical trial matching and availability of a somatic cancer database. QIAGEN cited the company’s brand recognition, patient data review services, clinical trial data gathering and real-world evidence abilities as attractive.

QIAGEN also announced the expected purchase of Formulatrix’s digital PCR assets for $125 million in cash and future milestone payments up to $135 million. QIAGEN plans to introduced a fully integrated, automated digital PCR solution in 2020, featuring multiplexing capabilities and higher throughput than systems that are currently available. “As the use of digital PCR continues to emerge and gains utility across a wide range of applications in Life Sciences, we plan for expansion into applications for Molecular Diagnostics,” commented QIAGEN CEO Peer M. Schatz. Formulatrix said that the sale will allow it to focus on its protein crystallization and liquid handling businesses. The transaction is expected to be completed by the middle of the year, and be dilutive to 2019 adjusted EPS by around $0.03 per share and neutral in 2020.

Mr. Schatz told investors at the J.P. Morgan Healthcare Conference that N-of-One adds on-demand and real-world evidence services to its bioinformatics business, thus expanding the business’s end-users to include pharmaceutical companies, healthcare providers and payers. N-of-One has 41 employees and 8 oncologists that serve as consultants. In the digital PCR market, QIAGEN will take on established players Bio-Rad Laboratories and Thermo Fisher Scientific.